Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/51865
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAttapon Cheepsattayakornen_US
dc.contributor.authorRuangrong Cheepsattayakornen_US
dc.date.accessioned2018-09-04T06:10:47Z-
dc.date.available2018-09-04T06:10:47Z-
dc.date.issued2012-07-23en_US
dc.identifier.issn1574891Xen_US
dc.identifier.other2-s2.0-84863919123en_US
dc.identifier.other10.2174/157489112801619683en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84863919123&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/51865-
dc.description.abstractA number of recent studies revealed that successful treatment of the patients with MDR/XDR- TB was not achieved due to high resistant rates to many second-line drugs such as kanamycin and prothionamide including poor adherence of the lengthy treatment. Many new drugs and compounds such as benzothiazinones, meropenem, PA-824, isoflavonoids, rhein, PNU-100480, TMC207, SQ109, OPC-67683, AZD5847, and linezolid are currently in development pipeline. According to very few patents in new compounds and drugs against MDR/XDRMycobacterium tuberculosis bacilli have been currently introduced, so inventors must be encouraged to contribute to this area worldwide. © 2012 Bentham Science Publishers.en_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleNovel compounds and drugs and recent patents in treating multidrug-resistant and extensively drug-resistant tuberculosisen_US
dc.typeJournalen_US
article.title.sourcetitleRecent Patents on Anti-Infective Drug Discoveryen_US
article.volume7en_US
article.stream.affiliationsThailand Ministry of Public Healthen_US
article.stream.affiliationsChiang Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.